Indiabulls Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.50 Cr
as on 22-12-2024
- Paid Up Capital ₹ 6.28 Cr
as on 22-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 160.00 Cr
as on 22-12-2024
- Revenue 42.16%
(FY 2022)
- Profit 14.99%
(FY 2022)
- Ebitda 26.81%
(FY 2022)
- Net Worth -36.44%
(FY 2022)
- Total Assets 3.73%
(FY 2022)
About Indiabulls Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.50 Cr and a paid-up capital of Rs 6.28 Cr.
The company has closed loans amounting to ₹160.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Indiabulls Pharmaceuticals Limited India is Nikhil Chari as CEO. Vidya Nand, Anand Kumar, and Monika Panghal serve as directors at the Company.
- CIN/LLPIN
U33119HR2016PLC078088
- Company No.
078088
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2016
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Indiabulls Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikhil Chari  | CEO | 28-Jul-2016 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vidya Nand | Director | 20-Aug-2020 | Current |
| Anand Kumar | Director | 20-Aug-2020 | Current |
| Monika Panghal | Director | 22-Aug-2022 | Current |
Financial Performance of Indiabulls Pharmaceuticals.
Indiabulls Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.16% increase. The company also saw a substantial improvement in profitability, with a 14.99% increase in profit. The company's net worth observed a substantial decline by a decrease of 36.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indiabulls Pharmaceuticals?
In 2022, Indiabulls Pharmaceuticals had a promoter holding of 84.06% and a public holding of 15.94%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Oct 2017 | ₹30.00 Cr | Satisfied |
Others Creation Date: 05 Sep 2017 | ₹25.00 Cr | Satisfied |
Others Creation Date: 29 Aug 2017 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Indiabulls Pharmaceuticals?
Indiabulls Pharmaceuticals has a workforce of 340 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indiabulls Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indiabulls Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
